Is ImmunityBio, Inc. (IBRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.8% / 30% | 2.7% / 30% | 0.5% / 30% | 2.37% / 5% | ✓ HALAL |
| DJIM | 5.8% / 33% | 2.7% / 33% | 0.5% / 33% | 2.37% / 5% | ✓ HALAL |
| MSCI | 103.2% / 33% | 48.4% / 33% | 8.5% / 33% | 2.37% / 5% | ✗ NOT HALAL |
| S&P | 5.8% / 33% | 2.7% / 33% | 0.5% / 33% | 2.37% / 5% | ✓ HALAL |
| FTSE | 103.2% / 33% | 48.4% / 33% | 8.5% / 50% | 2.37% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 99.3% | |
| Operating Margin | -169.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -36.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$305M |
| Free Cash Flow | -$309M |
| Total Debt | $518M |
| Current Ratio | 5.1 |
| Total Assets | $502M |
Price & Trading
| Last Close | $7.38 |
| 50-Day MA | $7.64 |
| 200-Day MA | $3.75 |
| Avg Volume | 37.3M |
| Beta | -0.1 |
|
52-Week Range
$1.83
| |
About ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Purification Calculator
As a halal stock with 2.37% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ImmunityBio, Inc. (IBRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ImmunityBio, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ImmunityBio, Inc.'s debt ratio?
ImmunityBio, Inc.'s debt ratio is 5.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 103.2%.
Does ImmunityBio, Inc. require dividend purification?
Yes, ImmunityBio, Inc. has an impermissible income ratio of 2.37%, which means 2.37% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are ImmunityBio, Inc.'s key financial metrics?
ImmunityBio, Inc. has a market capitalization of $7.6B, and revenue of $113M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.